Skip to content

Technology
PIpeline
- Intranasal Naloxone
- Intranasal Epinephrine
About us
Contact
News
Investors

Technology
PIpeline
- Intranasal Naloxone
- Intranasal Epinephrine
About us
Contact
News
Investors

Press Releases

Choose Year
Search Press Releases

Found 11 Results

November 6, 2025

Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

October 8, 2025

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

September 2, 2025

Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

August 26, 2025

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

August 14, 2025

Nasus Pharma Announces Closing of Initial Public Offering

August 13, 2025

Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

February 28, 2025

Nasus Pharma to Present Positive Clinical Results from Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting

August 7, 2024

Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis

12 »

IR Contact

Mike Moyer
LifeSci Advisors
617-308-4306
mmoyer@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Unsubscribe

Loading...

Home
About us
Technology
Pipeline
Contact us

Investors Overview
News
Events
SEC Filings
Corporate Governance
Stock Information
Investor FAQs

Privacy policy
Cookies policy
Terms And Conditions Of Use

© 2025 Nasus Pharma All rights reserved

Scroll to Top